<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02641652</url>
  </required_header>
  <id_info>
    <org_study_id>ATRAX</org_study_id>
    <nct_id>NCT02641652</nct_id>
  </id_info>
  <brief_title>A Randomized Controlled Trial of Sertraline in Paroxysmal Arterial Hypertension</brief_title>
  <acronym>ATRAX</acronym>
  <official_title>A Randomized Controlled Trial of Sertraline in Paroxysmal Arterial Hypertension (ATRAX Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Olomouc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brno University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Anne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tomas Bata Hospital, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prerov Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Valasske Mezirici Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thomayerova Teaching Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vsetin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Olomouc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is currently no established treatment for paroxysmal hypertension, but selective
      serotonin reuptake inhibitors showed good effect in previous reports. This double-blind,
      placebo controlled, prospective multicenter clinical trial will assess the efficacy of
      sertraline on cessation or reduction of symptoms of paroxysmal arterial hypertension. 136
      patients with documented hypertensive paroxysms with abrupt elevations of blood pressure and
      distressful physical symptoms will be randomized in a 1:1 ratio to receive sertraline, 50 mg
      daily, or matching placebo as an add-on to their chronic medication. Effect of the treatment
      on patient symptoms, office and ambulatory blood pressure and side effects will be evaluated
      after 3 months. If proven effective, sertraline might become a standard treatment for this
      condition.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>difference in the rate of paroxysmal hypertension symptoms cessation between sertraline and placebo groups</measure>
    <time_frame>3 months of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>difference in the rate of paroxysmal hypertension symptoms reduction between sertraline and placebo groups</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>difference in the fall of mean office and ambulatory systolic and diastolic blood pressure between groups</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects of the treatment</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Sertraline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sertraline, 25 mg once daily for first 7 days, then 50 mg once daily for the rest of the trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>25 mg once daily for first 7 days, then 50 mg once daily for the rest of the trial</description>
    <arm_group_label>Sertraline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1/2 tablet once daily for first 7 days, then 1 tablet once daily for the rest of the trial</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Study will enroll adult patients (age &gt;18 years) with hypertensive paroxysms during the
        past 6 months (preferably during the past 6 weeks) - abrupt elevations of systolic blood
        pressure (BP) ≥20% compared to previous measured systolic BP value before paroxysm, or ≥20%
        compared to mean systolic BP on 24-hour ambulatory blood pressure monitoring (ABPM), or
        ≥20% compared to measured office systolic BP, documented by a clinician or home blood
        pressure monitor, requiring physician or emergency room visit or the use of any rescue
        antihypertensive medication. Hypertensive paroxysms may be accompanied by abrupt onset of
        one or more distressful physical symptoms, such as headache, chest pain, dizziness, nausea,
        palpitations, flushing, and diaphoresis.

        Exclusion Criteria:

        Pregnancy or breastfeeding, hypersensitivity to sertraline (Zoloft®) or of the the
        components of this drug. Current use of sertraline or any other selective serotonin
        reuptake inhibitor (SSRI), mono-amin oxidase (MAO) inhibitors, selegiline, moclobemide,
        linezolide, pimozide. Current use of other serotoninergic drugs (eg. tryptofane, triptane
        and other 5-HT agonists), tramadol or dopamine antagonists (including antipsychotics).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Vaclavik, MD. Ph.D. Assoc. Prof</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Olomouc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Vaclavik, MD. Ph.D. Assoc. Prof.</last_name>
    <phone>+420588442682</phone>
    <email>janvaclavik@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irena Opavska, Bc.</last_name>
    <phone>+420588443716</phone>
    <email>irena.opavska@fnol.cz</email>
  </overall_contact_backup>
  <link>
    <url>http://www.fnol.cz</url>
    <description>University Hospital Olomouc</description>
  </link>
  <link>
    <url>http://www.lf.upol.cz/en/</url>
    <description>Faculty of Medicine and Dentistry, Palacký University</description>
  </link>
  <reference>
    <citation>Mann SJ. Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment. Arch Intern Med. 1999 Apr 12;159(7):670-4. Review.</citation>
    <PMID>10218745</PMID>
  </reference>
  <reference>
    <citation>Eisenhofer G, Sharabi Y, Pacak K. Unexplained symptomatic paroxysmal hypertension in pseudopheochromocytoma: a stress response disorder? Ann N Y Acad Sci. 2008 Dec;1148:469-78. doi: 10.1196/annals.1410.019.</citation>
    <PMID>19120143</PMID>
  </reference>
  <reference>
    <citation>Pickering TG, Clemow L. Paroxysmal hypertension: the role of stress and psychological factors. J Clin Hypertens (Greenwich). 2008 Jul;10(7):575-81. Review.</citation>
    <PMID>18607143</PMID>
  </reference>
  <reference>
    <citation>Mann SJ. Severe paroxysmal hypertension (pseudopheochromocytoma). Curr Hypertens Rep. 2008 Feb;10(1):12-8. Review.</citation>
    <PMID>18367021</PMID>
  </reference>
  <reference>
    <citation>Vaclavik J, Krenkova A, Kocianova E, Vaclavik T, Kamasova M, Taborsky M. 7B.04: EFFECT OF SERTRALINE IN PAROXYSMAL HYPERTENSION. J Hypertens. 2015 Jun;33 Suppl 1:e93. doi: 10.1097/01.hjh.0000467601.49032.62.</citation>
    <PMID>26102972</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>December 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Palacky University</investigator_affiliation>
    <investigator_full_name>Jan Vaclavík</investigator_full_name>
    <investigator_title>Jan Václavík, MD. Ph.D. Assoc. Prof.</investigator_title>
  </responsible_party>
  <keyword>paroxysmal hypertension</keyword>
  <keyword>pseudopheochromocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

